SAN FRANCISCO, October 4, 2026 – The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, a global leader in oncology, is set to take place from February 11 to 13, 2027, in San Francisco. The symposium brings together the largest international audience in GU oncology, uniting urologic, medical, and radiation oncologists with diagnostic and interventional radiologists in multidisciplinary discussions that drive innovation in the field. This year’s theme, ‘Pioneering Breakthroughs, Optimizing Patient Outcomes,’ reflects the event’s focus on translating scientific discoveries into clinical practice.
Abstract submissions for the 2027 Symposium opened prior to the stated deadline and remain open through October 13, 2026, at 11:59 PM Eastern Time (ET). The ASCO GU program is expanding its commitment to groundbreaking science by increasing the number of oral presentations, encouraging researchers to share findings from novel clinical trials and translational studies.
Jose A. Karam, MD, FACS, Chair of the 2027 Symposium and a faculty member at The University of Texas MD Anderson Cancer Center, emphasized that the symposium serves as a trusted source for paradigm-shifting discoveries and offers researchers a unique platform to present their work to a broad audience representing all GU specialties. He urged investigators to take advantage of the expanded oral presentation opportunity to showcase innovative research in person.
The Program Committee, under Dr. Karam’s leadership, is seeking submissions of phase III clinical trials, as well as phase I and II trials, to be presented as podium presentations alongside posters, with a particular interest in translational research and correlative studies that can guide individualized patient care. Presenting at the symposium, designated #GU27, offers more than data dissemination; it provides critical exposure, opportunities to connect with experts, and a pathway to deliver practice-changing science.
Taigo Kato, MD, PhD, from the University of Osaka in Japan, noted that his accepted abstract at the 2026 Symposium was a significant honor, garnered attention from the GU oncology community—including coverage by UroToday—and facilitated new international collaborations expected to influence the field. Pooja Ghatalia, MD, of Fox Chase Cancer Center, described presenting as especially meaningful due to the years of multidisciplinary team effort and patient contributions behind the research.
She emphasized that the value extends beyond the presentation itself, enabling engagement with colleagues on future research directions, sparking new ideas and collaborations, and identifying unresolved questions before data can enter routine care. Both presenters encouraged early-career investigators to submit their work, stressing that ASCO GU’s exclusivity to GU cancer offers unique networking opportunities with like-minded researchers.
Dr. Ghatalia advised that submitters need not have all answers resolved, recommending they ask important questions, tell a clear story, and submit even if early in their research journey, as feedback, mentorship, and connections from the symposium can have lasting impacts on their careers. The overarching goal of the 2027 Symposium, as stated by Dr. Karam, is to see breakthrough science and clinical trials presented that improve patient outcomes and advance the field.
The Cancer Letter, the source of this information, has been a leading authority on oncology issues since 1973. No financial figures, market impacts, or economic data related to the symposium’s funding, sponsorship, attendance costs, or associated expenditures are included in the provided source material.
